Quince Therapeutics, Inc. (QNCX)

Market Cap	7.63M -89.0%
Revenue (ttm)	n/a
Net Income	-56.98M
EPS	-1.21
Shares Out	55.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,291,701
Open	0.1494
Previous Close	0.1501
Day's Range	0.1348 - 0.1538
52-Week Range	0.1251 - 4.5500
Beta	1.24
Analysts	Hold
Price Target	10.00 (+7,199.27%)
Earnings Date	Mar 23, 2026

About QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX
• Website: https://www.quincetx.com

Analyst Summary

According to 3 analysts, the average rating for QNCX stock is "Hold." The 12-month stock price target is $10.0, which is an increase of 7,199.27% from the latest price.

Price Target

$10.0

(7,199.27% upside)

Analyst Consensus: Hold